The Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases (NCIRD) awarded an indefinite-delivery, indefinite-quantity (IDIQ) contract to Merck Sharp & Dohme LLC, doing business as Merck, for the supply of various adult vaccines. The contract has a potential value of $87,753,075 and a period of performance from July 1, 2023 through June 30, 2024. The vaccines will be delivered within 15 business days of order receipt and shipped FOB...
The Centers for Disease Control and Prevention awarded multiple indefinite delivery contracts to Merck Sharp & Dohme LLC for adult vaccines. The contracts have a potential value of $83,485,760 and a period of performance from July 1, 2021 to June 30, 2022. Merck will provide 13 standard adult vaccines including hepatitis A, hepatitis B, pneumococcal polysaccharide, tetanus/diphtheria toxoids, herpes zoster, measles/mumps/rubella, meningococcal conjugate, human papillomavirus, and...
The Centers for Disease Control and Prevention (CDC) has awarded an Indefinite Delivery Contract (IDC) to Merck Sharp & Dohme LLC, doing business as Merck, for the supply of up to 23 standard pediatric vaccines. The $3.301 billion contract will run from April 1, 2022 through March 31, 2023, supporting the CDC's Immunization Awardees and the Vaccines for Children program under Section 317(j) of the Public Health Service Act. The vaccines being procured include a wide range such as DTaP, Hep...
The Centers for Disease Control and Prevention awarded multiple indefinite delivery contracts under a competitive solicitation to purchase standard adult vaccines. The contracts have a one year period of performance from July 1, 2022 to June 30, 2023 and a combined potential value of $85.6 million. Merck Sharp & Dohme LLC was awarded one of these contracts as the prime contractor. The contracts enable the CDC to order 12 types of adult vaccines for delivery within 15 business days....
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Merck Sharp & Dohme LLC, doing business as Merck, for the purchase of 20 standard pediatric vaccines. The contract supports the CDC's Vaccines for Children program and adult vaccination initiatives under Section 317(j) of the Public Health Service Act. This multiple award IDC has a total ceiling value of $2,565,312,500 and a period of performance of 12 months from the award date...
The Department of Health and Human Services Centers for Disease Control and Prevention awarded a multiple award indefinite delivery contract to Merck Sharp & Dohme LLC, doing business as Merck, to provide 2019 Vaccines for Children. The contract has a potential value of $2,495,643,500.00 and a period of performance from April 1, 2019 to March 31, 2020. As a major pharmaceutical manufacturer, Merck will deliver a wide range of pediatric and adult vaccines to fulfill the Vaccines for...
The key points from the provided information are as follows: This is an Indefinite Delivery Contract (IDC) awarded by the Centers for Disease Control and Prevention (CDC) to the prime contractor Merck Sharp & Dohme LLC, doing business as Merck, a major pharmaceutical manufacturer. The contract has a ceiling value of $86,407,050 and a period of performance from July 1, 2019 to June 30, 2020. The purpose of this IDC is to provide a wide range of vaccines for adults, including MMR, varicella,...
This indefinite delivery contract was awarded by the Centers for Disease Control and Prevention (CDC) Office of Acquisition Services, a civilian agency, to Merck Sharp & Dohme Corp. The contract, which has a ceiling value of $129,202,465.56, is for the delivery of adult vaccines under the 2010-2011 Adult Vaccine Contract program. The contract has a period of performance from July 1, 2010 to June 30, 2011 and was not set aside for any specific socioeconomic category. It is a multiple award...
This is a multiple award Indefinite Delivery Contract awarded by the Centers for Disease Control and Prevention (CDC) to Merck Sharp & Dohme LLC, doing business as Merck, for the procurement of 27 pediatric vaccines to support the CDC's Immunization Awardees program and Vaccines for Children program. The contract has an estimated ceiling value of $4,079,096,100 and a period of performance from April 1, 2024 through March 31, 2025. The vaccines will be shipped F.O.B. destination to the 50...
The Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases (NCIRD) has awarded a 5-year, $154.3 million indefinite delivery, indefinite quantity (IDIQ) contract to Glaxosmithkline, LLC for the provision of various adult vaccines. The contract period of performance is from July 1, 2024 to June 30, 2025, with vaccines ordered via the CDC's Vaccine Tracking System (VTrckS) using a fair opportunity process. The required vaccine types include...